Is Diamondback Energy a Good Stock to Buy?
Diamondback Energy (FANG) is a lesser-known diamond in the rough…
Sell
43
DGX Quote, Financials, Valuation and Earnings
Last price:
$166.67
Seasonality move
:
13.74%
Day range:
$164.61 - $168.13
52-week range:
$125.42 - $178.87
Dividend yield:
1.81%
P/E ratio:
21.54x
P/S ratio:
1.90x
P/B ratio:
2.71x
Volume:
741.5K
Avg. volume:
1.2M
1-year change:
28.14%
Market cap:
$18.4B
Revenue:
$9.9B
EPS (TTM):
$7.69
Analysts' Opinion
-
Consensus RatingQuest Diagnostics has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 10 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $177.10, Quest Diagnostics has an estimated upside of 6.9% from its current price of $165.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $159.00 representing 4.02% downside risk from its current price of $165.66.
Fair Value
-
According to the consensus of 17 analysts, Quest Diagnostics has 6.9% upside to fair value with a price target of $177.10 per share.
DGX vs. S&P 500
-
Over the past 5 trading days, Quest Diagnostics has underperformed the S&P 500 by -5.83% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Quest Diagnostics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Quest Diagnostics has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Quest Diagnostics reported revenues of $2.6B.
Earnings Growth
-
Quest Diagnostics has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Quest Diagnostics reported earnings per share of $1.95.
Enterprise value:
24.3B
EV / Invested capital:
1.83x
Price / LTM sales:
1.90x
EV / EBIT:
17.37x
EV / Revenue:
2.46x
PEG ratio (5yr expected):
8.07x
EV / Free cash flow:
26.77x
Price / Operating cash flow:
20.64x
Enterprise value / EBITDA:
12.85x
Gross Profit (TTM):
$3.2B
Return On Assets:
5.88%
Net Income Margin (TTM):
8.82%
Return On Equity:
12.99%
Return On Invested Capital:
7.24%
Operating Margin:
13.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $9.9B | $9.3B | $9.9B | $2.3B | $2.6B | |
| Gross Profit | $3.4B | $3.1B | $3.2B | $736M | $858M | |
| Operating Income | $1.4B | $1.3B | $1.3B | $267M | $361M | |
| EBITDA | $1.8B | $1.7B | $1.9B | $392M | $506M | |
| Diluted EPS | $7.92 | $7.49 | $7.69 | $1.70 | $1.95 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.1B | $2.7B | $1.9B | $2.4B | $2.4B | |
| Total Assets | $14B | $13.6B | $12.8B | $14B | $16.2B | |
| Current Liabilities | $1.8B | $1.8B | $1.6B | $1.8B | $2.2B | |
| Total Liabilities | $7.1B | $7B | $6.8B | $7.6B | $9.3B | |
| Total Equity | $6.9B | $6.6B | $6B | $6.4B | $6.9B | |
| Total Debt | $4.2B | $4.1B | $4.1B | $4.8B | $6.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.7B | $1.3B | $1.3B | $527M | $464M | |
| Cash From Investing | -$543M | -$1.1B | -$2.5B | -$114M | -$502M | |
| Cash From Financing | -$1.7B | $160M | $1.1B | $130M | -$170M | |
| Free Cash Flow | $1.3B | $864M | $909M | $455M | $341M | |
DGX
Sector
Market Cap
$18.4B
$39.2M
Price % of 52-Week High
92.62%
45.99%
Dividend Yield
1.81%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
28.14%
-38.63%
Beta (5-Year)
0.924
0.774
Dividend yield:
1.81%
Annualized payout:
$2.96
Payout ratio:
38%
Growth streak:
13 years
Technicals
8-day SMA
Sell
Level
$168.83
200-day SMA
Buy
Level
$154.27
Bollinger Bands (100)
Buy
Level
153.44 - 168.08
Chaikin Money Flow
Buy
Level
250.2K
20-day SMA
Sell
Level
$170.93
Relative Strength Index (RSI14)
Sell
Level
44.01
ADX Line
Sell
Level
7.53
Williams %R
Buy
Level
-83.2388
50-day SMA
Buy
Level
$164.63
MACD (12, 26)
Buy
Level
37.04
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Neutral
Level
355.3K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8068)
Buy
CA Score
(Annual)
Level (-0.0945)
Buy
Beneish M-Score
(Annual)
Level (-2.5412)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.4539)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Stock Forecast FAQ
In the current month, DGX has received 7 Buy ratings 10 Hold ratings, and 0 Sell ratings. The DGX average analyst price target in the past 3 months is $177.10.
-
Where Will Quest Diagnostics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Quest Diagnostics share price will rise to $177.10 per share over the next 12 months.
-
What Do Analysts Say About Quest Diagnostics?
Analysts are divided on their view about Quest Diagnostics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Quest Diagnostics is a Sell and believe this share price will drop from its current level to $159.00.
-
What Is Quest Diagnostics's Price Target?
The price target for Quest Diagnostics over the next 1-year time period is forecast to be $177.10 according to 17 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 10 analysts rate the stock a Hold.
-
Is DGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Quest Diagnostics is a Hold. 10 of 17 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of DGX?
You can purchase shares of Quest Diagnostics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Quest Diagnostics shares.
-
What Is The Quest Diagnostics Share Price Today?
Quest Diagnostics was last trading at $166.67 per share. This represents the most recent stock quote for Quest Diagnostics. Yesterday, Quest Diagnostics closed at $165.66 per share.
-
How To Buy Quest Diagnostics Stock Online?
In order to purchase Quest Diagnostics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is up 0.24% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is down 1.45% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 3.19% over the past day.
